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Abstract
Major Depressive Disorder (MDD) is a common disease seen every day by primary care
providers across the United States. According to the Centers for Disease Control and Prevention
(CDC, 2018), eight percent of all adults over the age of 20 suffer from depression, and a study by
the American Psychological Association found depressive disorders to cost roughly $71 billion
annually. Today, psychotherapy is the recommended first-line therapy for treating MDD, but
pharmacotherapy is more commonly used. Alternative forms of therapy are also being
researched in order to avoid the use of medication while adequately treating the symptoms of
MDD.
For this review, seven databases were searched including PubMed, Cochrane Database of
Systematic Reviews, PsycInfo, Cinahl, DynaMed, ClincalKey, and ScienceDirect from
September 1 to November 21, 2018. Works chosen for review were published after the year 2000
and included randomized controlled trials (RCTs), systematic reviews, and meta analyses. This
review found several benefits of using exercise to treat MDD while reducing risks, but exercise
alone is not superior in effectiveness to psychotherapy or pharmacotherapy. Overall, exercise
offers the greatest benefit in reducing MDD symptoms when used as an augmented therapy to
either psychotherapy or pharmacotherapy. Limitations of this literature review include lack of
studies with longevity or large sample sizes.
Key Terms pathophysiology, exercise, depression, SSRIs, selective serotonin reuptake
inhibitors, Major Depressive Disorder, MDD
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Introduction
On any given day, patients with the diagnosis of Major Depressive Disorder (MDD)
show up at least once on the schedule of primary care providers across the United States.
According to a recent study by the Centers for Disease Control and Prevention (CDC, 2018),
eight percent of all adults over the age of 20 suffer from depression within a given two-week
period, with women being twice as likely as men to be affected by the disorder. Of these
individuals, 80 percent reported at least some difficulty with completing daily activities due to
depressive symptoms. More specifically, 50 percent of them noted mild difficulty with home,
work, or social activities while 30 percent admitted to moderate or extreme difficulty based on
evaluation with the Patient Health Questionnaire-9 (PHQ-9). Researchers involved in the study
believe this is a conservative estimate, as there are more patients with depression who are
unwilling to participate in the survey (CDC, 2018). However, even when patients are evaluated
by a primary care provider for depressive symptoms, it has been found that the diagnosis of
MDD is all too commonly missed. DynaMed (2018) completed a study of 2,321 participants in a
primary care setting with 304 patients who screened positive for depression with the PHQ-9. Of
those 304 patients, only 31 percent were diagnosed with depression by the provider. To further
expand, 175 of those patients displayed significant depressive symptoms on the PHQ-9 and yet
only 37.7 percent were diagnosed with MDD at that visit (DynaMed, 2018).
The PHQ-9 is a screening tool commonly used in clinics when there is a concern for
depression in an individual, as it addresses the diagnostic criteria which must be met for the
diagnosis of MDD. To further expand, the diagnostic criteria is defined by the Diagnostic and
Statistical Manual of Mental Disorders-5 (DSM-V) which states in order for a patient to be
diagnosed with MDD, he or she must have a change in baseline causing significant impairment
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in daily activities due to experiencing at least five of the following symptoms most of the day,
nearly every day for a minimum of two weeks with at least one of the first two symptoms
present: 1) depressed mood; 2) decreased interest or pleasure in activities; 3) unintentional
change in weight or appetite; 4) insomnia or hypersomnia; 5) psychomotor agitation or
retardation; 6) fatigue; 7) excessive feelings of worthlessness or guilt; 8) decreased concentration
or indecisiveness; 9) recurrent thoughts of death or suicide. The DSM-V also requires that
symptoms may not be attributable to any other condition or substance. If the above criteria are
met, the diagnosis is then further classified based on the severity. Mild MDD can be defined as
the minimum number of symptoms present with symptoms causing distress that is manageable.
Moderate and severe MDD include an increased number of symptoms present as well as
increased impairment and difficulty managing symptoms. Due to the difficulty with managing
the symptoms of moderate or severe MDD, primary care providers will typically refer these
patients to a specialist for further evaluation and treatment (DynaMed, 2018).
If proper treatment is not initiated for those with depression, high societal costs and
greater functional impairment than associated with other chronic diseases such as diabetes and
arthritis can occur according to the CDC (2018). In fact, a study by the American Psychological
Association found depressive disorders to be the sixth-most-costly health condition overall with
$71 billion being spent annually, falling shortly behind conditions such as diabetes mellitus,
ischemic heart disease, low back and neck pain, hypertension, and injuries related to falls
(Winerman, 2017). Therefore, it is imperative that primary care providers across the United
States understand and implement proper treatment for their patients suffering from mild MDD.
Today, first line therapy for mild MDD is psychotherapy. The modality of psychotherapy with
the best evidence for efficacy according to DynaMed (2018) is cognitive behavioral therapy
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(CBT) which focuses on modifying behavior and functioning by refocusing dysfunctional beliefs
through social skills training, relaxation, coping skills, and behavioral activation. Although CBT
is recommended as first-line therapy, MDD is more commonly treated with medications such as
Selective Serotonin Reuptake Inhibitors (SSRIs). This tendency seems to occur for two reasons
with the first being pharmacotherapy appears to be more readily available especially from a rural
primary care standpoint, and secondly, many patients today want the “quick fix” they believe a
pill can offer rather than participating in the lengthy process that CBT involves. DynaMed
(2018) reported CBT has been found to reduce both symptoms and relapse rate more than SSRIs
in patients with mild MDD, but Jesulola, Micalos, and Baguley (2018) also reported up to 80
percent of patients with depression fail to respond to antidepressant therapy in clinical trials.
Recent research, however, shows treating patients with mild MDD with alternative therapies,
including exercise, may be just as beneficial as traditional therapies, while providing further
significant benefits, avoiding side effects, and limiting the use of medication (DynaMed, 2018).
The purpose of this scholarly project is to determine the role of exercise in treating adult
patients diagnosed with mild MDD in the primary care setting. Exercise will be assessed as a
stand-alone therapy compared to pharmacotherapy with SSRIs, as well as reviewed as an
augmented therapy to SSRIs. It is anticipated that exercise will provide benefits over SSRIs and
it will be useful as an augmented therapy, but it will not be superior alone. Further research will
be required to support the use of exercise as a sole therapy over SSRIs. A systematic analysis
will look at the efficacy of the two therapies regarding benefits, risks, and improvement of
symptoms.
Statement of the Problem
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With the increasing cost of medications and potential for high risk side effects, some
providers are recommending alternative therapies to SSRIs for adult patients diagnosed with
mild MDD in hopes of providing an option that is safer and more cost effective while providing
the same benefit. Further research is needed to show if exercise and SSRIs are equal in efficacy
in the reduction of symptoms associated with mild MDD in adults.
Statement of the Research Question
In adult patients diagnosed with mild MDD in a primary care setting, does treating with
exercise as a stand-alone therapy compared to treating with SSRIs adequately improve symptoms
while minimizing side effects?
Review of Literature
In this review, seven databases were searched including PubMed, Cochrane Database of
Systematic Reviews, PsycInfo, Cinahl, DynaMed, ClinicalKey, and ScienceDirect from
September 1 to November 21, 2018. Many key terms were searched in PubMed: Major
Depressive Disorder, exercise, SSRI, MDD, and pharmacotherapy. Cochrane Database of
Systematic Reviews was searched using the key terms exercise, depression, and SSRI. A search
of PsycInfo yielded results based on the key term SSRI. Key terms utilized in a search of
CINAHL included depression, exercise, Major Depressive Disorder, SSRI, and MDD. DynaMed
results were obtained by searching the key term MDD. A search of ClinicalKey yielded results
based on the key terms MDD, depression, and SSRI. Lastly, key terms used to search
ScienceDirect included depression and pathophysiology. Filters were applied to include only
peer reviewed articles published after the year 2000. Works chosen for review included
randomized controlled trials (RCTs), systematic reviews, and meta analyses. Sources excluded
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were those published prior to the year 2000, had poor study design, and those focused on severe
MDD or child and adolescent populations
Pathophysiology of MDD
MDD is a very common but serious chronic mental health disease characterized by
changes in mood, thoughts, behavior, and physical health that can take away a patient’s ability to
enjoy life and perform even the simplest daily tasks (Fekadu, Shibeshi, & Engidawork, 2016).
Even with years of extensive research on MDD, the exact pathophysiology remains unknown.
There are many theories that may answer the question of the underlying pathophysiology
including theories of neural circuitry, stress response circuits, genetic vulnerability and
environmental interaction, biogenic monoamine, inflammation, hormones, and circadian rhythm
(Fekadu et al., 2016). One of the most commonly accepted theories is the biogenic monoamine
theory which is the basis for pharmacologic treatment for MDD. In fact, this theory was
developed after the unexpected discovery of the first antidepressant drugs which were created for
other conditions but were found to increase the amount of monoamine neurotransmitters in the
brain by either blocking monoamine oxidase inhibitors (MAOI) or the reuptake of
neurotransmitters such as serotonin (Fekadu et al., 2016). Serotonin is involved in pain sensation,
appetite regulation, aggression, and mood, and the increased available amounts of serotonin
activity in the brain were found to decrease depressive symptoms. Later this knowledge was used
to create SSRIs which then became one of the primary treatment options for MDD.
Another potential theory discussed by Jesulola et al. (2018) considers the theories listed
previously as a combined source of pathogenesis rather than each theory individually, stating that
MDD is a complex disorder with multiple etiologies. To further expand, Jesulola et al. reported
environmental stress combined with genetic factors act on immunologic and endocrine responses
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to cause structural and functional changes in the brain leading to dysfunction of neurogenesis and
neurotransmission which ultimately causes the symptoms of depression.
Exercise in the Treatment of MDD
In the SMILE study completed by Blumenthal et al. (2007), 202 adults with the diagnosis
of major depression participated in a RCT with groups assigned to supervised group exercise,
home exercise, sertraline, or placebo pill for 16 weeks. Upon the completion of the 16 weeks,
outcomes were evaluated by the Hamilton Depression Rating Scale (HAM-D). Forty-one percent
of the participants were considered to be in remission as they no longer met the criteria for MDD
based on the HAM-D score. In fact, 45 percent of patients assigned to supervised group exercise
achieved remission, 40 percent of home exercisers, 47 percent of those on medication, and 31
percent of those with a placebo pill (p = 0.057). Results were not statistically significant (p =
0.23) when comparing patients treated with exercise or SSRIs compared to those with placebo
treatment. Due to the nature of the study, a double-blind set up was not possible. However, the
treatment team and outcome assessors were not aware which patients were participating in each
treatment group to minimize bias (Blumenthal et al., 2007).
A Cochrane Review by Cooney et al. (2013) pooled together results of 39 RCTs to
compare exercise versus control and pharmacological treatments in treating MDD. For the
purpose of this Cochrane Review, exercise was defined as “planned, structured, and repetitive
bodily movement done to improve one or more components of physical fitness” (Cooney et al.,
2013) and control interventions included no intervention, placebo intervention, and those in
which exercise was augmented to an already established treatment option such as CBT in both
exercising and non-exercising groups. Thirty-five of the studies focused on a comparison
between exercise and control, and exercise was found to be moderately more effective (SMD -

EXERCISE AS TREATMENT FOR MDD

11

0.62, 95% CI [-0.81, -0.42]). More specifically, type, intensity, duration and frequency of
exercise were all reviewed to determine the best form of exercise to treat MDD. This research
indicated either resistance (SMD -1.03, 95% [CI -1.52, -0.53]) or resistance combined with
aerobic exercise (SMD -0.85, 95% CI [-1.85, 0.15]) at a vigorous intensity (SMD -0.77, 95% CI
[-1.30, -0.24]) for 13 to 24 (SMD -0.70, 95% CI [-1.09, -0.31]) or 25 to 36 sessions (SMD -0.80,
95% CI [-1.30, -0.29]) produced the largest clinical effect on reducing depressive symptoms
(Cooney et al., 2013).
Additionally, the outcomes of the four trials included in the review that compared
exercise to pharmacological treatments indicated no statistically significant difference (SMD 0.11, 95% CI [-0.34, 0.12]) between the two treatment options. A weakness of this review lies in
the fact that not all RCTs included used the same evaluation tool, instead, Beck Depression
Inventory (BDI), HAM-D, and a variety of other scales were used to measure depression
symptom outcomes. Many of the RCTs included were also small and had many methodological
weaknesses. The review also touched on potential biases and noted while they try to avoid any
biases, the authors mentioned a certain degree of bias was inevitable due to “asymmetrical funnel
plot” with more positive trials being published than negative trials, therefore, more positive trials
were included in the research (Cooney et al., 2013).
A systematic review by Danielsson, Noras, Waern, and Carlsson (2013) examined the
quality of evidence available for using exercise in the treatment of MDD through a compilation
of statistics from fourteen RCTs. The RCTs included compared exercise to antidepressants,
exercise to physical activity, and exercise as an augmented therapy to traditional treatment versus
traditional treatment alone. Exercise was again defined as “planned, structured, and repetitive
bodily movement done to improve one or more components of physical fitness” (Danielsson et
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al., 2013). The comparison between exercise and antidepressants was reviewed in two trials and
two long-term follow-up studies. The results showed no statistically significant difference
between exercise and antidepressants regarding depression severity in either the short (SMD 0.06, 95% CI [-0.36, 0.23]) or long term (SMD -0.19, 95% CI [-0.68, 0.31]). Exercise versus
physical activity was reviewed in eight studies with the result indicating there is no difference in
the effect of the two (SMD 0.01, 95% CI [-0.23 to 0.24]). Lastly, four studies included data on
exercise as an augmented therapy versus traditional treatment alone. This data indicated there
was a small effect on those treated with exercise as an augmented therapy compared to those
who were not (SMD -0.44, 95% CI [-0.79, -0.09]) (Danielsson et al., 2013).
The positive effects of exercise on depressive symptoms are proposed to include both
psychological and neurobiological mechanisms (Danielsson et al., 2013). Psychological effects
proposed include diversion from depressive thinking as well as increased self-efficacy and selfconfidence. Neurobiological effects proposed include changes in endorphin and monoamine
levels similar to those in patients treated with antidepressants. Recent studies also suggest
exercise stimulates hippocampal neurogenesis to improve depressive symptoms. The weaknesses
noted in the study design include variations in the methodology of each RCT, small and varying
sample sizes, and lack of standardized outcome measuring tool (Danielsson et al., 2013).
A RCT by Dunn, Trivedi, Kampert, Clark, and Chambliss (2005) aimed to address the
efficacy of exercise in the treatment of depression, specifically whether there is a dose-response
relationship. The study contained 80 adult patients diagnosed with mild to moderate MDD who
were evaluated before the study with the 17-item Hamilton Rating Scale for Depression
(HRSD17) and then again after 12 weeks of treatment. During treatment, there were four
exercise groups and a placebo group. The first two groups exercised at a low dose energy
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expenditure of 7 kcal/kg/week, with one of the low dose (LD) groups exercising 3 days per week
and the other 5 days per week. The second two groups exercised at a higher energy expenditure
of 17.5 kcal/kg/week which was consistent with the public health recommendations. One of the
public health dose (PHD) groups exercised 3 days per week and the other for 5. Lastly, the
placebo group performed stretching and flexibility exercise for just 15 to 20 minutes 3 times per
week. All exercise was performed in a supervised laboratory for 12 weeks (Dunn et al., 2005).
Dunn et al. (2005) found that HRSD17 scores steadily decreased with each week of
exercise. At 12 weeks, the scores of the PHD groups significantly improved (-47% from
baseline, p<0.001) and LD groups were less effective, but still improved (-30%, p=0.006).
Groups exercising 3 and 5 days per week both improved with relatively equal efficacy (-39%, p
<0.001 and -38%, p <0.001), and the control group improved only slightly (-29%, p=0.02).
Overall, PHD exercise was significantly more effective than LD exercise in improving HRSD17
scores at 12 weeks (p=0.04 and p=0.03 respectively). In fact, those in the PHD group exercising
5 days per week had the greatest response in reducing HRSD17 scores and a total of 20
participants were able to achieve remission, defined as HRSD17 score of less than or equal to 7
(Dunn et al., 2005).
Another RCT by Bartholomew, Morrison, and Ciccolo (2005) consisted of 40
participants already diagnosed with and receiving treatment for MDD. The study aimed to
determine if “a single bout of moderate-intensity aerobic exercise would improve mood and
well-being” in these patients (Bartholomew et al., 2005). Participants were randomly assigned to
an exercise or control group with the exercise group participating in 30 minutes of exercise at 60
to 70 percent of age-predicted maximal heart rate, while the control group simply participated in
a 30-minute period of quiet rest. Outcomes of mood improvement were measured by both the

EXERCISE AS TREATMENT FOR MDD

14

Profile of Mood States (POMS) and Subjective Exercise Experiences Scale (SEES) 5 minutes
prior to treatment as well as 5, 30, and 60 minutes following treatment. Effect size was then
labeled as “d” to indicate mean differences in the change scores. Overall, no significant
differences were noted between the exercise and control groups regarding improvement of
depressive symptoms (all p>0.15). The only statistically significant difference noted was the
change in positive well-being in the exercise group over the resting group at 5 and 30 minutes
after treatment (p<0.01, d=1.13 and 1.06 respectively) (Bartholomew et al., 2005).
SSRIs in the Treatment of MDD Including MOA, Benefits, and Risks
A review by Garnock-Jones and McCormack (2010) on the use of escitalopram, a
commonly used first-line SSRI, in the treatment of MDD included both short and long-term
trials. Only well-designed trials with at least 100 patients were included, and each trial utilized
randomization, double-blind, and multiple approaches to comparisons between escitalopram and
placebo or another medication. The review not only compared trials for efficacy of the drug, but
also provided background information on the pharmacodynamics, side effects, and benefits of
the SSRI. Garnock-Jones and McCormack (2010) stated escitalopram provides antidepressant
effects by selective, dose-dependent inhibition of the serotonin transporter (SERT) which causes
inhibition of serotonin reuptake into presynaptic nerve terminals ultimately leading to increased
extracellular serotonin levels.
The results concluded that in the short-term trials escitalopram was more effective than
placebo and just as effective as other SSRIs or antidepressants in treating MDD. Escitalopram
was found to have a rapid onset and significant antidepressant effects with 35.2 percent of
escitalopram treated patients compared to 21.5 percent of placebo patients reporting a 20 percent
decrease in the HAM-D17 score (p=0.008). In fact, escitalopram produced a significantly higher
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response rate than placebo in all but two trials included in the review (Garnock-Jones &
McCormack, 2010).
Moreover, escitalopram showed greater efficacy in preventing relapse in the long-term
trials over placebo and was just as effective as other antidepressants. Outcomes in long-term
studies included in the review were based on change in MADRS score from baseline or time to
relapse. In two long-term studies comparing escitalopram to placebo, those treated with
escitalopram had significantly longer timeframes to relapse than those in the placebo treatment
group (ESC: 252 and 188 days versus PL: 130 and 56 days respectively, p<0.05) and rate of
recurrence was also significantly higher among placebo participants (ESC: 27 and 26 percent
versus PL: 65 and 40 percent respectively, p<0.05) (Garnock-Jones & McCormack, 2010).
Garnock-Jones and McCormack (2010) noted the most common side effects found in the
two fixed-dose trials in the review were mild to moderate in severity and included nausea,
ejaculation disorder, insomnia, diarrhea, somnolence, dry mouth, rhinitis, fatigue, influenza-like
symptoms, dizziness, and increased sweating. Occurrence rates of adverse effects among patients
treated with escitalopram 10 and 20 mg daily versus those in the placebo group were 66 percent
and 86 percent versus 61 percent. Overall, it is a well-tolerated medication with a rapid onset. It
has a low risk for drug interactions and side effects and may provide the benefit of cost
effectiveness over many other antidepressants (Garnock-Jones & McCormack, 2010).
Strengths of the study lie within the various inclusion criteria. Only studies on adult
populations were included and those including patients with severe MDD or suicidal ideations
were excluded from the review. Outcomes were evaluated based on either the MADRS or HAMD17. However, variety amongst the individual studies makes it difficult to directly compare
results to compile a review (Garnock-Jones & McCormack, 2010).
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A meta-analysis by Li, Shen, Lou, and Li (2017) pooled together the results from four
clinical trials examining the efficacy of escitalopram in the treatment of MDD. The four clinical
trials included 649 participants with a formal diagnosis of MDD who were started on
escitalopram as monotherapy and again evaluated for depressive symptom improvement at the
end of a two-week period. Average change in HAMD17 score was most significant in patients
with moderate-severe depression, but scores also significantly improved in those with mild and
moderate depression (15.0+/-7.9, 12.4+/-5.0, and 12.9+/-6.8 respectively). In those with only
mild depression, the response rate was 76.9 percent and remission was 64 percent. Overall, the
authors found that the more severe the depressive symptoms were at the beginning of the study,
the less responsive the patient will be to escitalopram as monotherapy (Li et al., 2017).
Adverse effects and safety of the drug were also evaluated during the trials. Amongst the
four trials included, there were 479 adverse events with the most common being mild to
moderate gastrointestinal symptoms such as nausea, dry mouth, and dyspepsia. No serious
adverse events were noted. The group of participants as a whole showed promising data for
escitalopram being a suitable and safe treatment option for patients with MDD (Li et al., 2017).
Strengths of the analysis lie within the study design as only trials with similar
methodology of randomization, double-blind, and active control were included. Only adult
patients were included and those who were not in good physical health or had a recent history of
substance abuse were excluded. This helped control the participant sample for a more consistent
finding. Additionally, Li et al. (2017) graded outcomes of depressive symptoms with the
HAMD17 score for a more consistent grading of the outcome. One weakness of the analysis
according to the authors was the inability to fully complete a high-quality meta-analysis due to
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the missing information including raw data and unpublished versions of the studies reviewed (Li
et al., 2017).
A Cochrane Review by Arroll et al. (2009) pooled together results of 14 RCTs with a
total of 2283 participants to compare antidepressants to placebo in the treatment of MDD. Of the
studies included, four RCTs examined SSRIs compared to placebo while the others focused on
different antidepressants. Within these four studies, the rate of beneficial outcomes associated
with SSRI use was significantly greater than that of placebo (1.28, 95% CI [1.15, 1.43]) and risk
for harm was quite low (1.03, 95% CI [0.87, 1.21]) (Arroll et al., 2009).
A weakness of the study lies in the short duration of the studies, as most lasted for only 6
to 8 weeks which is hardly enough time for the medications to become fully effective. A variety
of outcome tools were also used to measure depressive symptoms throughout, although most
commonly used were the HAMD17 and MADRS, therefore the authors chose to only include
data based on these two scores to create a SMD. A strength, however, comes from the inclusion
criteria applied in the reviewing process. Studies with the majority of participants over the age of
65 were excluded and studies including patients with co-existing conditions were also excluded
(Arroll et al., 2009).
Discussion
As knowledge of the underlying pathophysiology of MDD continues to develop,
recommended treatment also continues to evolve. Alternative therapies such as exercise are
being considered in the treatment of mild MDD, but each treatment plan must be individualized
to maximize benefits while minimizing risks. The next section is a discussion of the review of
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literature of exercise compared to SSRIs in the treatment of adult patients with mild MDD in the
primary care setting.
Exercise in the treatment of MDD
Dunn et al. (2005) and Bartholomew et al. (2005) both concluded exercise alone was
effective at improving depressive symptoms. However, the degree of improvement varied. Dunn
et al. found the effects of exercise to be dose dependent. When it was completed at a higher dose
and intensity, effects were greater. Specifically, exercise at a PHD, or 17.5 kcal/kg/week, was
found to be an effective option for mild MDD by reducing HRSD17 scores by 47 percent from
baseline. This improvement in depressive symptoms was significantly greater than that found in
the LD and control groups. In fact, Dunn et al. concluded exercise at a PHD 3 or more times per
week was just as effective as traditional therapy options for treating mild MDD, although the
various treatment options were not directly compared in the RCT. Bartholomew et al. concluded
30 minutes of either exercise or rest equally reduced depressive symptoms, but only exercise
improved positive well-being. Unfortunately, the increase in positivity was short-lived as it
returned to baseline by the 60-minute post-exercise evaluation.
Dunn et al. (2005) also noted the benefits of exercise over medication or CBT include the
reduction of risk for mortality from diseases such as cardiovascular disease and obesity which
further supports the recommendation to use exercise to treat MDD by primary care providers.
Unfortunately, the studies by Dunn et al. and Bartholomew et al. (2005) were not without
weaknesses as participants were unable to be blinded to treatment assignment due to the nature
of the treatment. The sample sizes were also small, and the studies lacked longevity. Lastly, all
exercise in the RCT by Dunn et al. was completed in a supervised lab which weakens the ability
to apply the findings to the general population. Overall, the studies indicated exercise can be a
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beneficial treatment option for MDD once further research is completed to correct for
weaknesses (Dunn et al., 2005).
SSRIs in the treatment of MDD including MOA, benefits, and risks
Garnock-Jones and McCormack (2010), Li et al. (2017), and Arroll et al. (2009) all found
SSRIs to be an effective treatment for mild MDD. Garnock-Jones and McCormack (2010) and
Arroll et al. both concluded SSRIs are more effective than placebo in treating MDD. GarnockJones and McCormack (2010) specifically focused on escitalopram and found it to be more
effective than other SSRIs and antidepressants. Li et al. also found escitalopram to be an
effective monotherapy in treating MDD, although it was not compared to other medications, and
the effectiveness was based on the severity of the MDD with the greatest effects found in those
with mild MDD. Garnock-Jones and Mccormack (2010) also reviewed long-term studies in order
to develop a better understanding of escitalopram. Escitalopram showed greater efficacy in
preventing relapse in the long-term trials over placebo and was, again, just as effective as other
antidepressants.
All three studies found SSRIs to be relatively safe. Garnock-Jones and McCormack
(2010) did note a variety of side effects throughout the studies included, but the only side effects
noted were mild to moderate in intensity and incidence increased with a higher dose of the
medication. Overall, escitalopram was found to have a rapid onset, provide effective antidepressant effects, and be more cost effective than other antidepressant medications.
Unfortunately, not all participants responded appropriately to the use of the medication. Li et al.
(2017) also found escitalopram to be safe. Throughout the four studies included in their research,
the most common adverse effects were mild gastrointestinal symptoms, and therefore the drug
was found to be favorably safe. Lastly, Arroll et al. (2009) found the risk for harm of SSRIs to be
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minimal. The results indicated SSRIs are an appropriate choice for treating MDD in primary
care, although the number needed to treat (NNT) was seven for SSRIs, meaning it is likely that
one patient will benefit from treatment with the drug while six will not.
The review by Garnock-Jones and McCormack (2010) comparing escitalopram to both
placebo and other antidepressants minimized bias and weaknesses by only including welldesigned trials with larger sample sizes. Li et al. (2017), however, included small sample sizes
and lacked longevity, and additional research is needed to better understand predictors of
therapeutic response. Likewise, no specific recommendations regarding dose and duration of
SSRI treatment were formulated through the review by Arroll et al. (2009). Additional studies on
the use of SSRIs need to be completed to further specify the recommendations for SSRI use in
MDD.
Exercise compared to SSRIs in the treatment of MDD
Blumenthal et al. (2007) found exercise to be comparable to antidepressant medication in
treating patients with MDD. This study corrected for weaknesses found in previous studies by
comparing exercise not only to antidepressants, but also to a placebo pill. This helped ensure
effects with antidepressant medication was not just based on the placebo of taking a pill.
Blumenthal et al. saw higher remission rates in both those treated with supervised or at home
exercise (45 and 40 percent respectively) and antidepressants (47 percent) compared to those in
the placebo group (31 percent) after 16 weeks of treatment. The exact mechanism as to how
exercise produced the anti-depressive effects remains unknown, although Blumenthal et al.
suggested numerous psychological factors that may contribute including “increased self-efficacy,
a sense of mastery, positive thoughts, distraction from negative thoughts, and enhanced selfconcept” as well as biologic pathways including “increased central norepinephrine
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neurotransmission, alterations in the hypothalamo-pituitary-adrenocortical axis, and increased
secretion of amine metabolites as well as serotonin synthesis and metabolism” (Blumenthal et
al., 2007).
On the contrary, Cooney et al. (2013) found exercise to be less effective than
antidepressants or psychological therapy and only moderately more effective than control in
improving depressive symptoms. When only high-quality studies were included in the review,
the effects of exercise over control were further reduced. Similarly, Danielsson et al. (2013)
concluded there was no significant difference in the antidepressant effects of exercise compared
to antidepressants through the four studies included reviewing the two. Eight trials comparing
exercise to physical activity, such as stretching or meditation, found no statistical difference in
the effects between the two, and results obtained by both methods was proposed to be a result of
increased self-efficacy, coping skills, social support, or encouragement during the activity.
However, Danielsson et al. did conclude that exercise is beneficial as an augmentation to
medication in treating MDD, which is useful information for primary care providers in
recommending treatment options.
Unfortunately, each of the studies presented with weaknesses that need to be corrected
for in future research. The RCT by Blumenthal et al. (2007) concluded findings consistent with
many other previous meta-analyses, but it contained methodological barriers and lacked
longevity which makes it impossible to conclude the exact efficacy of using exercise to treat
MDD. Likewise, Danielsson et al. (2013) noted grade of evidence for their findings was low
secondary to many methodological weaknesses noted in the trials included. Future studies with
sound methodology and large sample sizes can correct for this deficit and help support the use of
exercise as an alternative to antidepressants.
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Cooney et al. (2013) noted a slightly different weakness. This review included 39 trials
which gave a variety of results to develop a summarized conclusion, but the variety also
provided a source of weakness as many evaluation tools were used throughout the 30 trials to
determine outcomes of the treatment methods. The authors noted there is an inevitable bias in the
results as more positive than negative trials are published and therefore included in the research.
Overall, the authors conclude extensive research is still needed to recommend exercise as an
alternative therapy over traditional treatments for MDD (Cooney et al., 2013).
Applicability to Clinical Practice
With depression being one of the most common illnesses seen by primary care providers
today, understanding all current treatment options available is essential. CBT is the
recommended first-line treatment for mild MDD, but the convenience of pharmacotherapy has
appealed to the majority of patients and SSRIs have become first-line in treating MDD. These
medications, however, do not come without risks. Therefore, it is important that primary care
providers be educated on the alternative forms of therapy that may be of equal benefit without
the added risks of medication. The information provided in this literature review allows
clinicians to make an educated decision on the recommendation for alternative forms of
treatment for MDD based on clinical evidence. Benefits of using exercise in the treatment of
MDD include, but are not limited to, minimizing medication use, avoiding side effects, reducing
cost, improving self-confidence, aiding in weight loss, and improving overall health.
Research on this topic is becoming very popular, but unfortunately, current research
includes more women than men and lacks longevity. At this point in the research, exercise is
noted to have a moderate effect on depression, but after correcting for the bias found in current
research, the effect may only be small (Cooney et al., 2013). There is not enough data to
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recommend specific type and intensity of exercise to produce the best results, and long-term antidepressive effects after exercise has concluded has not been studied sufficiently. Future research
should correct for these aspects to further the knowledge on this potential alternative therapy.
Overall, while exercise cannot be reported as a superior therapy over traditional options such as
pharmacotherapy or psychotherapy, it can be recommended as a beneficial augmented therapy
option in addition to the traditional treatments for all patients with MDD.
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